DK3315131T3 - Terapeutisk middel mod fibrose - Google Patents
Terapeutisk middel mod fibrose Download PDFInfo
- Publication number
- DK3315131T3 DK3315131T3 DK16814513.4T DK16814513T DK3315131T3 DK 3315131 T3 DK3315131 T3 DK 3315131T3 DK 16814513 T DK16814513 T DK 16814513T DK 3315131 T3 DK3315131 T3 DK 3315131T3
- Authority
- DK
- Denmark
- Prior art keywords
- fibrosis
- therapeutic agent
- therapeutic
- agent
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3315131T3 true DK3315131T3 (da) | 2022-11-14 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16814513.4T DK3315131T3 (da) | 2015-06-25 | 2016-06-24 | Terapeutisk middel mod fibrose |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (enExample) |
| EP (2) | EP3315131B1 (enExample) |
| JP (3) | JP6974167B2 (enExample) |
| KR (1) | KR102647942B1 (enExample) |
| CN (2) | CN107708697B (enExample) |
| AU (1) | AU2016284531B2 (enExample) |
| BR (1) | BR112017028137B1 (enExample) |
| CA (1) | CA2990791A1 (enExample) |
| DK (1) | DK3315131T3 (enExample) |
| ES (1) | ES2928684T3 (enExample) |
| HU (1) | HUE060732T2 (enExample) |
| MA (1) | MA42266A (enExample) |
| MX (2) | MX381792B (enExample) |
| MY (1) | MY191219A (enExample) |
| PH (1) | PH12017502322B1 (enExample) |
| PL (1) | PL3315131T3 (enExample) |
| PT (1) | PT3315131T (enExample) |
| RU (1) | RU2729630C2 (enExample) |
| SG (2) | SG10201912684TA (enExample) |
| WO (1) | WO2016208744A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| BR112017028137B1 (pt) * | 2015-06-25 | 2023-04-04 | Taiho Pharmaceutical Co., Ltd | Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste |
| DK3583943T3 (da) | 2017-02-15 | 2024-10-14 | Taiho Pharmaceutical Co Ltd | Farmaceutisk sammensætning |
| EP3682882A4 (en) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co., Ltd. | ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER |
| KR20210060465A (ko) | 2018-09-18 | 2021-05-26 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물과 아비라테론의 병용 요법 |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4094814B2 (ja) | 1998-04-28 | 2008-06-04 | 敏一 中村 | 血管新生抑制剤 |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| US7728017B2 (en) * | 2005-11-30 | 2010-06-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Met and uses thereof |
| CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| EP2215085B1 (en) * | 2007-10-25 | 2011-09-07 | AstraZeneca AB | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| JP4667537B2 (ja) | 2008-04-10 | 2011-04-13 | 大鵬薬品工業株式会社 | アシルチオウレア化合物又はその塩、及びその用途 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| MX2012008898A (es) * | 2010-02-03 | 2012-11-06 | Incyte Corp | Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met. |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| BR112017028137B1 (pt) * | 2015-06-25 | 2023-04-04 | Taiho Pharmaceutical Co., Ltd | Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste |
-
2016
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181692T1 (hr) | Liječenje fibroze | |
| BR112016021682A2 (pt) | cenicriviroc para o tratamento da fibrose | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| IL246978A0 (en) | Novel pharmaceutical formulations | |
| DK3174868T3 (da) | Forbindelser, der er aktive mod bromodomæner | |
| GB201513540D0 (en) | Therapeutic agents | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3262066T4 (da) | Genterapi | |
| ZA201600079B (en) | Active mixtures | |
| GB201509893D0 (en) | Therapeutic agents | |
| DK3192518T3 (da) | Anti-inflammatorisk middel | |
| GB201517263D0 (en) | Therapeutic agents | |
| DK3256462T3 (da) | Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel | |
| PT3353336T (pt) | Elétrodo | |
| HUE060732T2 (hu) | Terápiás szer fibrózisra | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3393478T3 (da) | Kombinationsterapi | |
| GB201509885D0 (en) | Therapeutic agents | |
| DK3248597T3 (da) | Terapeutisk middel til sensorineuralt høretab | |
| EP3308781A4 (en) | BLOOD PRESSURE CENTER | |
| DE112016003067A5 (de) | Leckreduzierte Drehdurchführung | |
| GB201509888D0 (en) | Therapeutic agents | |
| EP3334447A4 (en) | CCK2R-drug conjugates | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| BR112017011897A2 (pt) | métodos de tratamento da fibrose |